Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
Yahoo Finance ·
In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals ( VRTX 1.31% ) and Crinetics Pharmaceuticals ( CRNX +98.74% ) announced in a joint press release that Vertex is acquiring Crinetics. This won’t come cheap, to put it mildly; it’s a premium-priced deal that will cost billions of dollars. Here’s a look at whether that’s likely to be capital well spent. Vertex is paying $85 per share to acquire Crinetics, to be paid entirely in cash. This values the latter pharmaceutical company at approximately $10 billion, or roughly $8.8 billion when accounting for the cash and short-term investments Crinetics has on hand. As for the per-share price, $85 is slightly more than double the level at which Crinetics closed on Monday.
DYAX Investor Sentiment
Bullish (Long) 61% · Bearish (Short) 39%
289 participants
Related News
- Why Bank of America Stock Jumped in June
- SpaceX Just Made Its Biggest Acquisition Yet. Here's What It Means for the Stock.
- Warren Buffett's Successor, Greg Abel, Has 30% of Berkshire Hathaway's $343 Billion Investment Portfolio Tied Up in 2 Foundational AI Stocks
- Ceasefire collapse swings oil market from surplus fears to near-term panic: Saxo Bank
- Amazon expands rapid delivery product range in Brazil
- Commvault Systems (CVLT) Launches Recovery Simulation, Is The Stock 14% Overvalued?